Pharmaceuticals

Elixiron's enrupatinib shows promise in targeting neuroinflammation, with early data suggesting cognitive benefits and a new biomarker-guided path for therapy.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

Xeris Biopharma secures a new patent for its rare disease drug KEVEYIS until 2039, a strategic move to fend off generic competition and lock in revenue.

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

Leveraged finance titans turned a personal fight into a philanthropic powerhouse, raising a record $4.3M to fund the science that’s turning the tide on melanoma.

With over 55,000 on waitlists for the UK's first oral weight-loss pill, the market is set to explode. But strict rules and high hopes face a reality check.

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

An Arizona nonprofit’s innovative sweepstakes, driven by a personal mission, is accelerating gene therapy for childhood blindness. A new model for impact.

A projected 14.9% CAGR signals a gold rush in Alzheimer's agitation treatment. New, safer drugs are replacing risky antipsychotics, offering hope to millions.

With a promising cancer therapy but precarious finances, Propanc Biopharma's stock buyback raises a critical question: is it a sign of confidence or a high-stakes gamble?

A new FDA-approved therapy from Boehringer Ingelheim and a liquid biopsy from Guardant Health offer the first targeted initial treatment for HER2-mutant NSCLC.

Sweeping data from EHA 2026 shows Syndax's Revuforj achieving remarkable success across leukemia settings, signaling a new standard of care and a major market coup.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

Relmada Therapeutics poaches a Sage neurosteroid expert for its sepranolone program. A look at the strategic rationale behind a move that signals big ambitions.

Stunning head-to-head trial data shows Takeda's zasocitinib is 2.5x more effective than its rival, signaling a major market disruption and validating a landmark deal.

Philip Morris International holds its dividend steady, signaling stability to investors. But can consistent payouts mask the risks of its smoke-free revolution?

A record $1.3B IPO, a minister's endorsement, and a new $75M fund. Apotex's TSX debut isn't just a corporate win; it's a national strategy in motion.

A key deal locking in generic drug prices is extended, promising billions in savings for healthcare and providing crucial stability for a fragile industry.

A key clinical trial completion in Japan signals a major shift in prostate cancer care, heralding the arrival of advanced PSMA-targeted theranostics.